

# Cornelis J M Melief

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/339430/publications.pdf>

Version: 2024-02-01

54  
papers

8,532  
citations

147801

31  
h-index

175258

52  
g-index

54  
all docs

54  
docs citations

54  
times ranked

10835  
citing authors

#	ARTICLE	IF	CITATIONS
1	ISA101 and nivolumab for HPV-16 <sup>+</sup> cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
2	Special Review: The future of Immunotherapy. Immunotherapy Advances, 2021, 1, .	3.0	5
3	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2021, 9, 583-597.	3.4	9
4	Therapeutic cancer vaccines. Nature Reviews Cancer, 2021, 21, 360-378.	28.4	630
5	Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicology Reports, 2020, 7, 768-771.	3.3	79
6	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science Translational Medicine, 2020, 12, .	12.4	83
7	Editorial: Novel Strategies for Anti-Tumor Vaccines. Frontiers in Immunology, 2019, 10, 3117.	4.8	7
8	Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Molecular Immunology, 2018, 93, 115-124.	2.2	15
9	Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication. , 2018, 6, 146.		50
10	Smart delivery of vaccines. Nature Materials, 2018, 17, 482-483.	27.5	18
11	Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System. Journal of Immunology, 2018, 201, 87-97.	0.8	16
12	Precision T-cell therapy targets tumours. Nature, 2017, 547, 165-167.	27.8	23
13	Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFN $\hat{\imath}$ <sup>3</sup> - and TNF $\hat{\imath}$ <sup>±</sup> -Mediated Antiproliferative Effects and Necroptosis. Frontiers in Immunology, 2016, 7, 496.	4.8	26
14	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. Cancer Research, 2016, 76, 6017-6029.	0.9	108
15	Inflammasome-Dependent Induction of Adaptive NK Cell Memory. Immunity, 2016, 44, 1406-1421.	14.3	67
16	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research, 2016, 22, 2342-2350.	7.0	132
17	Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer, 2016, 16, 219-233.	28.4	580
18	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget, 2016, 7, 67087-67100.	1.8	43

#	ARTICLE	IF	CITATIONS
19	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. <i>Cancer Immunology Research</i> , 2015, 3, 1042-1051.	3.4	68
20	Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. <i>Clinical Cancer Research</i> , 2015, 21, 781-794.	7.0	81
21	The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NF $\kappa$ B activation. <i>Nature Communications</i> , 2015, 6, 6537.	12.8	64
22	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243.	1.8	58
23	The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion. <i>ELife</i> , 2015, 4, .	6.0	48
24	CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2918-2927.	0.7	13
25	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	27.8	1,705
26	Scientific contributions toward successful cancer immunotherapy in The Netherlands. <i>Immunology Letters</i> , 2014, 162, 121-126.	2.5	1
27	Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. <i>Vaccine</i> , 2014, 32, 1654-1660.	3.8	22
28	Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand-Peptide Conjugates. <i>Cancer Immunology Research</i> , 2014, 2, 756-764.	3.4	83
29	Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 538-546.	3.4	29
30	IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation. <i>Journal of Immunology</i> , 2014, 192, 5813-5820.	0.8	14
31	Addition of interferon- $\gamma$ to the p53-SLP vaccine results in increased production of interferon- $\gamma$ in vaccinated colorectal cancer patients: A phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1581-1591.	5.1	50
32	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. <i>Journal of Translational Medicine</i> , 2013, 11, 88.	4.4	165
33	Selective Activation of Oxygen-Deprived Tumor-Infiltrating Lymphocytes through Local Intratumoral Delivery of CD137 Monoclonal Antibodies. <i>Cancer Discovery</i> , 2012, 2, 586-587.	9.4	3
34	Treatment of Established Lesions Caused by High-risk Human Papilloma Virus Using a Synthetic Vaccine. <i>Journal of Immunotherapy</i> , 2012, 35, 215-216.	2.4	15
35	The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1953-1963.	4.2	23
36	Synthetic Vaccine for the Treatment of Lesions Caused by High Risk Human Papilloma Virus. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 300-301.	2.0	16

#	ARTICLE	IF	CITATIONS
37	Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy. <i>Journal of Translational Medicine</i> , 2011, 9, 107.	4.4	3
38	Enhancement of proliferation and downregulation of TRAIL expression on CD8 <sup>+</sup> T cells by IL-21. <i>European Journal of Immunology</i> , 2010, 40, 2990-2992.	2.9	6
39	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11895-11899.	7.1	215
40	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. <i>New England Journal of Medicine</i> , 2009, 361, 1838-1847.	27.0	970
41	Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. <i>Nature Reviews Cancer</i> , 2008, 8, 351-360.	28.4	508
42	Cancer Immunotherapy by Dendritic Cells. <i>Immunity</i> , 2008, 29, 372-383.	14.3	474
43	Induction of Tumor-Specific CD4 <sup>+</sup> and CD8 <sup>+</sup> T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. <i>Clinical Cancer Research</i> , 2008, 14, 178-187.	7.0	346
44	Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. <i>Clinical Cancer Research</i> , 2008, 14, 169-177.	7.0	286
45	Association of cervical cancer with the presence of CD4 <sup>+</sup> regulatory T cells specific for human papillomavirus antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12087-12092.	7.1	201
46	High Number of Intraepithelial CD8 <sup>+</sup> Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer. <i>Cancer Research</i> , 2007, 67, 354-361.	0.9	369
47	Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4 <sup>+</sup> T-Cell Immunity against Early Antigens E2 and E6. <i>Cancer Research</i> , 2004, 64, 5449-5455.	0.9	277
48	Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. <i>European Journal of Immunology</i> , 2003, 33, 2645-2654.	2.9	164
49	Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. <i>Immunological Reviews</i> , 2002, 188, 177-182.	6.0	94
50	Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. <i>European Journal of Immunology</i> , 2001, 31, 146-155.	2.9	53
51	A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. <i>Journal of General Virology</i> , 2001, 82, 2131-2142.	2.9	25
52	Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28. <i>Journal of Experimental Medicine</i> , 2000, 192, 483-494.	8.5	100
53	p53: A Potential Target Antigen for Immunotherapy of Cancer. <i>Annals of the New York Academy of Sciences</i> , 2000, 910, 223-236.	3.8	45
54	BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. <i>British Journal of Haematology</i> , 1998, 103, 1109-1115.	2.5	9